Cargando…
Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC‐3G3) to patients with advanced soft tissue sarcoma
BACKGROUND: Olaratumab, a fully human monoclonal antibody, selectively binds to human platelet‐derived growth factor receptor alpha and blocks ligand binding. This study assessed the effect of olaratumab on the pharmacokinetics (PK) of doxorubicin and the safety of olaratumab alone and in combinatio...
Autores principales: | Villalobos, Victor M., Mo, Gary, Agulnik, Mark, Pollack, Seth M., Rushing, Daniel A., Singh, Arun, Van Tine, Brian A., McNaughton, Rhian, Decker, Rodney L., Zhang, Wei, Shahir, Ashwin, Cronier, Damien M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997100/ https://www.ncbi.nlm.nih.gov/pubmed/31821732 http://dx.doi.org/10.1002/cam4.2728 |
Ejemplares similares
-
Incidence and Management of Olaratumab Infusion-Related Reactions
por: Van Tine, Brian A., et al.
Publicado: (2019) -
Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma
por: Jones, Robin L., et al.
Publicado: (2018) -
Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
por: McGuire, William P., et al.
Publicado: (2018) -
A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors
por: Wagner, A. J., et al.
Publicado: (2017) -
Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer
por: Mo, Gary, et al.
Publicado: (2017)